Clinical Trial Update: A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. [Phase 3]

View source ↗

Summary

Global Phase 3 trial comparing Volrustomig plus chemotherapy versus pembrolizumab plus chemotherapy in metastatic non-small cell lung cancer; the study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Volrustomig

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Non-small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING